Amyloid Plaques Beyond Alzheimer’s Disease: Formation, Mechanisms, and Therapeutic Implications in Systemic Amyloidoses and Neurodegenerative Disorders

Amyloid Plaques Beyond Alzheimer’s Disease: Formation, Mechanisms, and Therapeutic Implications in Systemic Amyloidoses and Neurodegenerative Disorders

Abstract

Amyloid plaques are conventionally recognized as a pathological hallmark of Alzheimer’s disease (AD). However, the formation of amyloid aggregates is not exclusive to AD and extends to a diverse range of systemic amyloidoses and other neurodegenerative disorders. This report broadens the perspective on amyloid plaques, exploring their formation mechanisms, composition variations, impact on cellular function across different organ systems, and therapeutic strategies targeting these aggregates, focusing beyond the AD context. We discuss the commonalities and differences in amyloidogenic proteins, the influence of the microenvironment on amyloid formation and toxicity, and the latest advancements in imaging, diagnostics, and therapeutic interventions, including small molecules, antibodies, and gene therapies. This expanded view aims to provide a comprehensive understanding of amyloid plaques as a general pathological mechanism and highlights potential cross-therapeutic strategies for amyloid-related diseases.

1. Introduction

Amyloidosis is a condition characterized by the extracellular deposition of misfolded proteins in various tissues and organs. These protein aggregates, known as amyloid fibrils, form plaques that disrupt tissue architecture and impair organ function. While Alzheimer’s disease (AD) is perhaps the most well-known example, associated with amyloid-beta (Aβ) plaques in the brain, amyloidosis is a systemic phenomenon. This report aims to explore the broader spectrum of amyloidosis, encompassing both systemic and neurological forms, and to move beyond the AD-centric view. Systemic amyloidoses, such as amyloid light chain (AL) amyloidosis, transthyretin (ATTR) amyloidosis, and AA amyloidosis, involve the deposition of different proteins in organs such as the heart, kidney, liver, and peripheral nerves. Neurodegenerative diseases like Parkinson’s disease (PD), Huntington’s disease (HD), and prion diseases also involve the aggregation of specific proteins, often forming intracellular rather than extracellular aggregates, but sharing common mechanistic principles with amyloid plaque formation. Understanding the shared mechanisms of amyloid formation and toxicity across these diverse diseases is crucial for developing effective therapeutic strategies that transcend disease-specific approaches.

2. Mechanisms of Amyloid Formation: A Universal Process

The formation of amyloid plaques is a complex process involving multiple steps, including protein misfolding, oligomerization, fibril formation, and plaque deposition. While the specific proteins involved differ across various amyloidoses, the underlying mechanisms share common principles. The process typically begins with a conformational change in a normally soluble protein, leading to exposure of hydrophobic regions. These hydrophobic regions promote self-assembly, initially forming small, soluble oligomers. These oligomers are often considered to be the most toxic species, as they can disrupt cellular membranes and interfere with protein function. The oligomers then aggregate further to form protofibrils, which elongate and intertwine to create mature amyloid fibrils. These fibrils deposit extracellularly or intracellularly, depending on the specific protein and the cellular environment, forming plaques.

2.1 Protein Misfolding and Nucleation: The initial misfolding event can be triggered by various factors, including genetic mutations, post-translational modifications (e.g., glycosylation, phosphorylation), oxidative stress, and chaperone dysfunction. The critical step is the formation of a stable nucleus or seed, which then acts as a template for further aggregation. This nucleation process can be either homogeneous (spontaneous self-assembly) or heterogeneous (seeded by pre-existing fibrils or other molecules). The rate of nucleation is often the rate-limiting step in amyloid formation.

2.2 Oligomerization and Fibril Elongation: Oligomers are intermediate species formed during amyloid fibril formation. These are typically soluble and can exist in various sizes and shapes. They are thought to be highly toxic, disrupting cellular membranes, inhibiting proteasome function, and triggering inflammatory responses. Fibril elongation occurs as monomers or oligomers add to the ends of existing fibrils. This process is highly dependent on the concentration of the amyloidogenic protein and the presence of cofactors, such as glycosaminoglycans (GAGs) and apolipoproteins, which can accelerate fibril formation and stabilization. The structure of amyloid fibrils is characterized by a cross-β sheet architecture, where polypeptide chains are arranged perpendicular to the fibril axis, forming a highly stable and resistant structure.

2.3 Factors Influencing Amyloid Formation: Several factors influence the rate and extent of amyloid formation, including protein concentration, pH, ionic strength, temperature, and the presence of chaperones and inhibitors. Molecular chaperones, such as heat shock proteins (HSPs), play a crucial role in preventing protein misfolding and aggregation. Inhibitors of amyloid formation include small molecules that bind to amyloidogenic proteins and prevent their self-assembly, as well as antibodies that recognize and neutralize amyloid oligomers and fibrils.

3. Compositional Variations in Amyloid Plaques: Beyond Amyloid-beta

While Aβ plaques are characteristic of AD, amyloid plaques in other diseases differ in their protein composition. In AL amyloidosis, the plaques are composed of immunoglobulin light chains produced by clonal plasma cells. In ATTR amyloidosis, the plaques are composed of transthyretin, a transport protein for thyroxine and retinol. The composition of plaques not only affects their physical properties but also their interactions with the surrounding tissue and their overall toxicity.

3.1 Systemic Amyloidoses: In AL amyloidosis, the deposited light chains can be full-length or fragments, and their amino acid sequence determines their propensity to aggregate and their target organ specificity. In ATTR amyloidosis, both wild-type and mutant forms of transthyretin can form amyloid plaques. Wild-type ATTR amyloidosis, also known as senile systemic amyloidosis, typically affects the heart and is associated with aging. Mutant ATTR amyloidosis is caused by genetic mutations in the TTR gene and can affect the heart, nerves, and other organs. AA amyloidosis is associated with chronic inflammation and involves the deposition of serum amyloid A (SAA) protein, an acute-phase reactant produced by the liver. The specific clinical manifestations of systemic amyloidoses depend on the affected organs and the amount of amyloid deposited.

3.2 Neurodegenerative Disorders: Beyond AD, other neurodegenerative diseases involve the aggregation of different proteins. In Parkinson’s disease, α-synuclein aggregates to form Lewy bodies and Lewy neurites, which are intracellular inclusions found in neurons in the substantia nigra and other brain regions. In Huntington’s disease, mutant huntingtin protein containing an expanded polyglutamine repeat aggregates to form intracellular inclusions in neurons in the striatum and cortex. Prion diseases, such as Creutzfeldt-Jakob disease (CJD), involve the misfolding and aggregation of prion protein (PrPSc), which can induce the conversion of normal prion protein (PrPC) into the pathogenic form. These protein aggregates differ in their structure and location (intracellular vs. extracellular), but they all share the common feature of causing cellular dysfunction and neurodegeneration.

4. Impact on Neurons and Other Cells: Mechanisms of Toxicity

Amyloid plaques exert their toxic effects through multiple mechanisms, including disruption of cellular membranes, interference with protein function, activation of inflammatory responses, and induction of oxidative stress. The specific mechanisms of toxicity may vary depending on the type of amyloidogenic protein, the location of the plaques, and the cell types affected.

4.1 Membrane Disruption: Amyloid oligomers and fibrils can disrupt cellular membranes, leading to ion channel dysfunction, calcium dysregulation, and cellular damage. The hydrophobic nature of amyloid aggregates allows them to insert into lipid bilayers, forming pores that compromise membrane integrity. This membrane disruption can lead to cell death by apoptosis or necrosis.

4.2 Interference with Protein Function: Amyloid plaques can interfere with the function of various proteins, including enzymes, receptors, and transporters. The plaques can physically block or sequester these proteins, preventing them from performing their normal functions. This can lead to a wide range of cellular dysfunctions, depending on the specific proteins affected. For example, Aβ plaques can interfere with synaptic transmission, impairing learning and memory in AD.

4.3 Inflammatory Responses: Amyloid plaques can activate inflammatory responses, leading to the release of cytokines and chemokines that contribute to tissue damage. Microglia and astrocytes, the resident immune cells of the brain, are activated by amyloid plaques and release inflammatory mediators, such as TNF-α, IL-1β, and IL-6. These inflammatory mediators can exacerbate neuronal damage and contribute to disease progression. In systemic amyloidoses, amyloid plaques can activate macrophages and other immune cells, leading to chronic inflammation and organ dysfunction.

4.4 Oxidative Stress: Amyloid plaques can induce oxidative stress, leading to the production of reactive oxygen species (ROS) and oxidative damage to cellular components. ROS can damage DNA, proteins, and lipids, contributing to cell death and tissue damage. Amyloidogenic proteins themselves can generate ROS, or they can interfere with the antioxidant defense mechanisms of cells.

4.5 Organ-Specific Effects: The specific effects of amyloid plaques on organ function depend on the affected organ and the type of amyloidogenic protein. In the heart, amyloid plaques can infiltrate the myocardium, leading to restrictive cardiomyopathy and heart failure. In the kidney, amyloid plaques can deposit in the glomeruli, leading to proteinuria and renal failure. In the peripheral nerves, amyloid plaques can damage nerve fibers, leading to neuropathy and sensory deficits. In the brain, amyloid plaques can disrupt synaptic transmission, impair neuronal function, and cause neurodegeneration.

5. Imaging and Diagnostics: Visualizing Amyloid Beyond the Brain

Accurate and early diagnosis of amyloidosis is crucial for effective treatment. Several imaging and diagnostic techniques are available for detecting amyloid plaques in various tissues and organs.

5.1 Biopsy and Histopathology: Tissue biopsy followed by histopathological examination with Congo red staining is the gold standard for diagnosing amyloidosis. Congo red staining causes amyloid fibrils to exhibit a characteristic apple-green birefringence under polarized light. Immunohistochemistry can be used to identify the specific type of amyloidogenic protein in the plaques.

5.2 Amyloid PET Imaging: Positron emission tomography (PET) imaging with amyloid-binding tracers is used to visualize amyloid plaques in the brain. Several PET tracers are available, including Pittsburgh Compound B (PiB), florbetapir, flutemetamol, and florbetaben. These tracers bind to Aβ plaques with high affinity and allow for the quantification of amyloid burden in the brain. Amyloid PET imaging is used to diagnose AD, monitor disease progression, and assess the efficacy of anti-amyloid therapies. Newer tracers are being developed to detect other types of amyloid, such as tau and α-synuclein.

5.3 Cardiac Imaging: Cardiac imaging techniques, such as echocardiography and cardiac magnetic resonance imaging (MRI), can be used to detect cardiac amyloidosis. Echocardiography can reveal thickening of the ventricular walls and diastolic dysfunction, while cardiac MRI can detect amyloid deposition and assess cardiac function. Recent advances in cardiac MRI, such as T1 mapping and extracellular volume (ECV) quantification, allow for more sensitive detection of cardiac amyloidosis. Furthermore, technetium-99m pyrophosphate (99mTc-PYP) scintigraphy is used to diagnose ATTR cardiac amyloidosis.

5.4 Serum and Urine Tests: Serum and urine tests can be used to detect amyloidogenic proteins and monitor disease progression. Serum free light chain assays are used to diagnose AL amyloidosis and monitor response to treatment. Serum transthyretin levels and genetic testing for TTR mutations are used to diagnose ATTR amyloidosis. Urine protein electrophoresis and immunofixation can detect monoclonal proteins associated with AL amyloidosis.

5.5 Mass Spectrometry: Mass spectrometry is a powerful technique for identifying and quantifying amyloidogenic proteins in tissue biopsies and serum samples. Laser capture microdissection followed by mass spectrometry can be used to isolate and identify amyloid plaques from tissue sections. Mass spectrometry can also be used to characterize the structure and modifications of amyloidogenic proteins.

6. Therapeutic Strategies: Targeting Amyloid Across Diseases

Therapeutic strategies for amyloidosis aim to reduce amyloid burden, inhibit amyloid formation, and alleviate symptoms. These strategies include small molecules, antibodies, gene therapies, and supportive care.

6.1 Small Molecules: Several small molecules are being developed to inhibit amyloid formation and promote amyloid clearance. Tafamidis is a small molecule that stabilizes the transthyretin tetramer, preventing its dissociation and subsequent amyloid formation. It is approved for the treatment of ATTR amyloidosis. Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) that also stabilizes the transthyretin tetramer and is used off-label for the treatment of ATTR amyloidosis. Other small molecules being investigated include inhibitors of β-secretase (BACE inhibitors) and γ-secretase, which are enzymes involved in the production of Aβ in AD. However, BACE inhibitors have shown limited efficacy and significant side effects in clinical trials.

6.2 Antibodies: Monoclonal antibodies that target amyloid oligomers and fibrils are being developed for the treatment of AD and other amyloidoses. Aducanumab, lecanemab, and donanemab are monoclonal antibodies that target Aβ plaques and are approved for the treatment of early-stage AD. These antibodies bind to Aβ plaques, promote their clearance by microglia, and slow cognitive decline. However, they are associated with potential side effects, such as amyloid-related imaging abnormalities (ARIA), including cerebral edema and microhemorrhages. Antibodies are also being developed to target other amyloidogenic proteins, such as α-synuclein and prion protein.

6.3 Gene Therapies: Gene therapies are being developed to reduce the production of amyloidogenic proteins or to enhance their clearance. Antisense oligonucleotides (ASOs) and RNA interference (RNAi) are used to reduce the expression of amyloidogenic genes. Patisiran and inotersen are ASOs that target transthyretin mRNA and are approved for the treatment of hereditary ATTR amyloidosis. Gene editing techniques, such as CRISPR-Cas9, are being explored to correct genetic mutations that cause amyloidosis. Viral vectors are used to deliver genes encoding antibodies or enzymes that degrade amyloid plaques.

6.4 Supportive Care: Supportive care is an important aspect of managing amyloidosis. This includes treating the symptoms of the disease, such as heart failure, renal failure, and neuropathy. Nutritional support and physical therapy can help improve quality of life. In some cases, organ transplantation may be necessary.

6.5 Emerging Therapeutic Strategies: Novel therapeutic strategies are being explored for amyloidosis, including immunotherapy, chaperone therapy, and stem cell therapy. Immunotherapy involves stimulating the immune system to clear amyloid plaques. Chaperone therapy involves using small molecules to stabilize proteins and prevent their misfolding. Stem cell therapy involves transplanting stem cells into damaged tissues to promote regeneration. These strategies are still in early stages of development, but they hold promise for the treatment of amyloidosis.

7. Future Directions: A Systems Biology Approach

Future research on amyloid plaques should focus on a systems biology approach, integrating data from genomics, proteomics, metabolomics, and imaging to gain a more comprehensive understanding of the disease. This will involve identifying novel biomarkers for early diagnosis, developing more effective therapeutic strategies, and personalizing treatment based on individual patient characteristics.

7.1 Identifying Novel Biomarkers: Identifying novel biomarkers for early diagnosis is crucial for improving treatment outcomes. This includes developing more sensitive and specific assays for detecting amyloidogenic proteins in serum, urine, and cerebrospinal fluid. Metabolomics and proteomics can be used to identify metabolic and protein signatures that are associated with amyloidosis. Imaging techniques, such as PET and MRI, can be used to monitor disease progression and assess the efficacy of therapeutic interventions.

7.2 Developing More Effective Therapeutic Strategies: Developing more effective therapeutic strategies will require a better understanding of the mechanisms of amyloid formation and toxicity. This includes identifying novel targets for drug development, such as inhibitors of amyloid nucleation, oligomerization, and fibril elongation. Combination therapies that target multiple pathways may be more effective than single-agent therapies. Personalized medicine approaches, based on individual patient characteristics, may improve treatment outcomes.

7.3 Addressing the Role of the Microenvironment: The microenvironment plays a crucial role in amyloid formation and toxicity. Understanding the factors that influence amyloid formation in different tissues and organs is essential for developing targeted therapeutic strategies. This includes studying the role of inflammatory cells, extracellular matrix components, and other environmental factors. Developing strategies to modulate the microenvironment may be beneficial for preventing amyloid formation and promoting amyloid clearance.

8. Conclusion

Amyloid plaques are a pathological hallmark not only of Alzheimer’s disease but also of a wide range of systemic amyloidoses and other neurodegenerative disorders. Understanding the shared mechanisms of amyloid formation and toxicity across these diverse diseases is crucial for developing effective therapeutic strategies that transcend disease-specific approaches. This report has provided a broadened perspective on amyloid plaques, exploring their formation mechanisms, composition variations, impact on cellular function, and therapeutic strategies. Future research should focus on a systems biology approach, integrating data from genomics, proteomics, metabolomics, and imaging to gain a more comprehensive understanding of the disease and to develop more effective and personalized treatment strategies. By moving beyond the AD-centric view, we can gain new insights into the pathogenesis of amyloidosis and develop more effective therapies for these devastating diseases.

References

• Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 297(5580), 353-356.
• Glenner, G. G. (1980). Amyloid deposits and amyloidosis. The β-fibrilloses. New England Journal of Medicine, 302(23), 1283-1292.
• Merlini, G., & Bellotti, V. (2003). Molecular mechanisms of amyloidosis. New England Journal of Medicine, 349(6), 583-596.
• Buxbaum, J. N. (2006). Systemic amyloidosis. Current Opinion in Rheumatology, 18(1), 71-79.
• Chiti, F., & Dobson, C. M. (2006). Protein misfolding, amyloid formation, and human disease: a mechanistic review. Annual Review of Biochemistry, 75, 333-366.
• Kelly, J. W. (2018). Structure and function in transthyretin amyloidosis. Cold Spring Harbor Perspectives in Medicine, 8(2), a025186.
• Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Mayer, A. (1989). Tau protein is a component of paired helical filaments and neurofibrillary tangles in Alzheimer’s disease. The EMBO Journal, 8(10), 13007-13017.
• Spillantini, M. G., Schmidt, M. L., Lee, V. M. Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). α-Synuclein in Lewy bodies. Nature, 388(6645), 839-840.
• Lansdorp, P. M. (2015). Are telomeres involved in the pathogenesis of systemic amyloidosis? Blood, 126(18), 2075-2076.
• Selkoe, D. J., & Schenk, D. (2003). Alzheimer’s disease: molecular understanding predicts amyloid-based therapeutics. Annual Review of Pharmacology and Toxicology, 43, 545-584.
• Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S. I., Merlini, G., Saraiva, M. J., … & Westermark, P. (2016). Amyloid nomenclature 2014: update and recommendations from the International Society of Amyloidosis Nomenclature Committee. Amyloid, 23(4), 209-213.
• Maurizio Cecchi, Flavio Giorgetti, Leonardo Marchese, and Giovanni Maria Tomaselli. 2023. Computational Approaches for Unveiling the Molecular Mechanisms of Protein Aggregation in Systemic Amyloidosis. International Journal of Molecular Sciences 24, no. 23: 16912. https://doi.org/10.3390/ijms242316912
• Doherty, C. M., LoPresti, V. L., & Reidy, K. J. (2023). Cardiac Amyloidosis: A Review. JAMA Cardiology, 8(12), 1226–1235. https://doi.org/10.1001/jamacardio.2023.3933